All News

sick kid child temperature fever

IVIg in MIS-C

d Jack Cush, MD

Among children with multisystem inflammatory syndrome (MIS-C), treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. MIS-C is a rare but serious pediatric condition associated with COVID-19 where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.

Read Article
Lknee.OA_.jpg

NSAIDs in Osteoarthritis: Study Suggests Need for New Look

d Jack Cush, MD

Knee osteoarthritis (OA) patients using nonsteroidal anti-inflammatory drugs (NSAIDs) showed greater loss of medial minimum joint space width than did others taking other drugs, registry data indicated.

Read Article
narcotics_0.jpg

Abrupt Cessation of Long-Term Opioid Prescribing Common

d MedPage Today

Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed.

Read Article
Johns Hopkins & UCSF Scleroderma pts tested for Abs against telomerase & shelterin (TERF1); while rare in RA, myositis, controls; TERF1 Abs seen in 9% of SSc & assoc w/ severe lung disease (OR 2.4) & shorter telomere length. (TERF1 found in 7% of IPF) https://t.co/e5ai8uO4kK

Links:

Dr. John Cush RheumNow ( View Tweet)

Abrupt Cessation of Long-Term Opioid Prescribing Common Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed. https://t.co/bCnaJHECd0 https://t.co/PfM9BCNPyC

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib when given to at-risk RA patients. https://t.co/RJD8CMouHK https://t.co/j8DMyxsaaf

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab, a bispecific mAb inhibits IL-7F & IL-17A, was testedin PhIII trial in Active psoriasis and show to be more effective than ustekinumab and placebo. 567 PSO pts - at wk 16, PASI90 was BMKZ 85% vs Ustekinumab 50%, vs 5% in placeob (p<0·0001) https://t.co/Z4ZQEHO4rX

Links:

Dr. John Cush RheumNow ( View Tweet)

Vagal Nerve Stimulation in Rheumatoid Arthritis Lancet Rheumatology has reported the results of a proof of concept trial, wherein vagal nerve stimulation was shown to ameliorate rheumatoid arthritis (RA) disease activity. https://t.co/XKH0ZY2A7E https://t.co/41nIxMb3e6

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic Podcast from Last week. iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/dfSTkSbY2d QD Clinics (123-127; Feb 5) QD127 - Chronic Monarthritis QD126 - Fever by the Numbers QD125 - "What Were You Thinking" QD124 - No Win Consults QD123 - When RA Meets UC https://t.co/ReOFOVooje

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Biobank examined the association between comorbidities & uric acid (SUA). Comorbidities assoc w/ increasing SUA. For each 1 mg increase in SUA, there is a 1-3 fold incr risk of HTN, IHD, CCF, ^HL, CKD https://t.co/ZEPAPRq62k

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Tofacitinib Safety Concerns - covering vagal nerve stimulation, IL-23 in PsA, Diet & RA, NSAIDs & COVID, Plaquenil side effects and more. Watch it here>> https://t.co/7RDZ0avZLC ListeniTunes>>https://t.co/FHJv01AAbC or SoundCloud>>https://t.co/yJWJNa6CRL

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Chronic Monarthritis Treatment Considerations on Chronic Monarthritis https://t.co/7VmH1skHhb

Links:

Dr. John Cush RheumNow ( View Tweet)

Download available--30 FDA Approved Biologics in Rheumatology https://t.co/HSvllkDUz7

Links:

Dr. John Cush RheumNow ( View Tweet)

Abrupt Cessation of Long-Term Opioid Prescribing Common Medicare beneficiaries were increasingly likely to have long-term opioid therapy stopped in recent years and medication changes often were abrupt, not tapered, an observational study showed. https://t.co/bCnaJHECd0 https://t.co/ermkbK6LMN

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Tofacitinib Safety Concerns Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow. https://t.co/7RDZ0avZLC https://t.co/iUJFuf8PNj

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - What Were You Thinking Pet Peeve Issues in Patient Care https://t.co/BpjXbsdWr5

Links:

Dr. John Cush RheumNow ( View Tweet)

HCQ Fails to Prevent COVID-19 Mounting evidence shows that HCQ is ineffective in COVID-19 infection; and now the NEJM reports that HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons. https://t.co/lt71GAtL3D https://t.co/VzmJgQlrrG

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz) when given to at-risk rheumatoid arthritis patients. https://t.co/RJD8CMouHK https://t.co/bipwWlIhiB

Links:

Dr. John Cush RheumNow ( View Tweet)
PSOLAR study of 298 pregnancies in 220 women with mod-severe psoriasis. 82% resulted in live births and rates of spontaneous abortion and congenital anomalies same as US population. Biologic exposure pregnancy outcomes same as those not on biologics https://t.co/GKXyDGRILD

Links:

Dr. John Cush RheumNow ( View Tweet)

OpenSAFELY analysis shows that NSAIDs safe w/ COVID. Study 1: 1/2 million NSAID users vs ~2 mill non-users found no difference in COVID-19 death (HR 0.96); Study 2: 1.7 million RA/OA pts, 10% on NSAIDs had a lower risk of COVID-19 death (HR 0.78) https://t.co/1f3JBmaf2e

Links:

Dr. John Cush RheumNow ( View Tweet)

×